A method and apparatus for an inspection cell that allows contact lenses to be presented in a known orientation to an operator or vision system for inspection. The cell can be tipped to allow the inspected lens to be placed into a known pick-cup location upon passing inspection, or if the lens does not pass inspection, it can be discarded. The placement or discarding of the lens can be readily automated by selecting the rate at which the cell is tipped.
|
1. An inspection cell for optical devices comprising:
a block of optically transparent material having a concave bowl and a spillway formed in an exterior surface thereof, said spillway integrated with the bowl; and
a retainer for holding the block via a pivot point that allows the block to tip.
9. A method for inspecting lens comprising the steps of:
providing a block of optically transparent material having a concave bowl and a spillway formed in an exterior surface thereof, said spillway integrated with the bowl;
pivotally mounting the block within a retainer that allows the block to tip;
filling the bowl with a fluid;
placing a lens in the bowl; and
tipping the bowl to empty the fluid and the lens.
2. The inspection device of
3. The inspection device of
5. The inspection device of
6. The inspection device of
7. The inspection device of
10. The method of
11. The method of
12. The method of
13. The method of
|
1. Field of the Invention
The present invention pertains to inspection cells for optical devices, and more particularly, to inspection cells for contact lenses that are adapted for easy or automated removal of lenses from the cell.
2. Description of the Prior Art
Prior art inspection of contact lenses is typically conducted on individual contact lenses within a separate flat bottom glass cell by manually placing the contact lens within the cell. These prior art inspection processes typically require that the contact lenses be manually flattened onto the bottom of the cell, cosmetically inspected using a comparator device, and then manually removed. Accepted lenses are manually placed into a packaging machine for further processing. It should be noted that prior art devices exist that include a non-articulated cell with a concave depression, the term non-articulated as used herein refers to a lack of features that provide for simple removal of the contact lens from the cell, or the device that holds the cell in place. The lack of articulated features within cells used by prior art inspection devices prevents the convenient movement of the contact lens without moving the device that holds the contact lens. These prior art inspection devices also fail to provide a mechanism for automated removal of the contact lenses from the cell, and do not even provide a simplified manual removal means.
Contact lenses have typically been transported from location to location in trays or vials. These trays or vials could be automatically filled with contact lenses but singulating the lenses after transportation has proved to be a quite difficult process to automate.
From the foregoing discussion, it should be apparent that there remains a need within the art for an inspection cell that is articulated to enable automated, or a simplified manual process, for removing the contact lenses from the cell once inspection is complete. There also remains a need within the art for a device that allows for simplified singulating of lenses after they have been inspected.
The present invention addresses the shortcoming within the prior art by providing an inspection cell that allows contact lenses to be presented in an orientation that is known to an operator or vision system for inspection. The cell can be tipped to allow the inspected lens to be placed into a known pick up location upon passing inspection, or if the lens does not pass inspection, it can be discarded. The placement or discarding of the lens can be readily automated by selecting the rate at which the cell is tipped.
These and other objects of the invention are provided by an inspection cell for optical devices having a block of essentially optically transparent material with a bowl formed therein, a spillway integrated with the bowl, a retainer for holding the block via a pivot point that allows the block to tip and a lens holder within the spillway.
Referring to
The water cell 5 of the invention, as illustrated in
The bowl 12 has a profile that is chosen to accommodate the desirable characteristics of rapid settling behavior for a small diameter bowl and the desirable optical characteristics of a large diameter bowl. Preferably, the bottom of the block 10 has a plano-convex lens formed within it. This plano-convex lens is sized to correct for any optical distortion caused by the bowl 12 to water interface. The preferred embodiment will employ the bowl 12 that contains a plano-convex lens, however, it is specifically envisioned that the bottom on the block 10 can remain flat and an external lens can be used to correct for anticipated optical distortions instead of forming the plano-convex on the bottom of the block 10.
The new water cell provides the ability to create inspection systems that can convey, inspect and dispense a lens in an automatic fashion without manual user intervention. The cell is designed such that the spherical or aspherical indentation both accommodates automatic centering upon settling and a clear optical path for inspection. The spillway 16 and pick-cup 18 are configured such that with proper selection of tipping speed and amount, a lens can be completely evacuated from the cell or accurately presented to a robotic manipulator for further processing.
It is envisioned that the inspection systems that will be used with water cell 5 be specifically designed to accommodate the features that are be provided by water cell 5 of the present invention. Inspection systems used with the water cell 5 are provided with an opportunity to view a three dimensional image of the contact lens as it rests within the water cell 5. It is known that applying a narrow aperture to a lens increases the depth of field that can be obtained in imaging systems. Inspection systems are specifically envisioned that can be used with the water cell 5 of the invention that allow the contact lens to be measured as a true three-dimensional object. The three-dimensional images of the contact lens in the target area can be made by applying a collimated beam of light to the water cell 5 containing the contact lens, focusing the light that emerges through the water cell 5 with a lens having a narrow aperture and then reflecting the light from the lens with a narrow aperture towards a display screen. The bottom of the block 10 can have a curvature or can be flat with an external lens used to compensate for the change in refractive indices from glass to water.
The inspection cell containing the lens is either presented to a vision system or a lens inspector to determine if the lens is cosmetically acceptable. If the lens is deemed to be “good”, the inspection cell is slowly rotated about the pivot point so that the lens is carried down the spillway and becomes lodged in the “lens pocket” at the end of the spillway. A robotic actuator then removes the lens from the lens pocket and places it into the next process stage (such as a blister package).
The foregoing discussion describes the embodiments most preferred by the inventors. Variations of these embodiments will be readily apparent to those skilled in the art. Accordingly, the scope of the invention should be measured by the appended claims.
Bergendahl, Marc, Lewison, David, Puffer, Jr., Raymond H.
Patent | Priority | Assignee | Title |
7477366, | Dec 07 2006 | COOPERVISION INTERNATIONAL LIMITED | Contact lens blister packages and methods for automated inspection of hydrated contact lenses |
Patent | Priority | Assignee | Title |
5443152, | Dec 21 1992 | Johnson & Johnson Vision Products, Inc. | Apparatus for carrying ophthalmic lenses |
5786898, | Aug 23 1996 | Structure and method for centrifugal sedimentation particle size analysis of particles of lower density than their suspension medium | |
EP686459, | |||
WO9981, | |||
WO9504264, | |||
WO3016855, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Oct 07 2003 | Bausch & Lomb Incorporated | (assignment on the face of the patent) | / | |||
May 25 2004 | BERGENDAHL, MARC | Bausch & Lomb Incorporated | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014800 | /0478 | |
Jun 05 2004 | LEWISON, DAVID | Bausch & Lomb Incorporated | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014800 | /0478 | |
Jun 10 2004 | PUFFER, JR , RAYMOND H | Bausch & Lomb Incorporated | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014800 | /0478 | |
Mar 20 2008 | B&L VPLEX HOLDINGS, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | BAUSCH & LOMB CHINA, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | BAUSCH & LOMB REALTY CORPORATION | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | BAUSCH & LOMB SOUTH ASIA, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | BAUSCH & LOMB TECHNOLOGY CORPORATION | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | Iolab Corporation | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | RHC HOLDINGS, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | SIGHT SAVERS, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | WILMINGTON MANAGEMENT CORP | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | B&L MINORITY DUTCH HOLDINGS LLC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | WILMINGTON PARTNERS L P | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | B&L SPAF INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | B&L FINANCIAL HOLDINGS CORP | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | B&L CRL PARTNERS L P | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | B&L CRL INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | WP PRISM INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | B & L DOMESTIC HOLDINGS CORP | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | Bausch & Lomb Incorporated | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
Mar 20 2008 | BAUSCH & LOMB INTERNATIONAL INC | CREDIT SUISSE | SECURITY AGREEMENT | 020733 | /0765 | |
May 18 2012 | Credit Suisse AG, Cayman Islands Branch | Bausch & Lomb Incorporated | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 028726 | /0142 | |
May 18 2012 | Bausch & Lomb Incorporated | CITIBANK N A , AS ADMINISTRATIVE AGENT | SECURITY AGREEMENT | 028728 | /0645 | |
May 18 2012 | EYEONICS, INC | CITIBANK N A , AS ADMINISTRATIVE AGENT | SECURITY AGREEMENT | 028728 | /0645 | |
Aug 05 2013 | CITIBANK N A , AS ADMINISTRATIVE AGENT | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST | 030995 | /0444 | |
Aug 05 2013 | CITIBANK N A , AS ADMINISTRATIVE AGENT | WP PRISM INC N K A BAUSCH & LOMB HOLDINGS INC | RELEASE OF SECURITY INTEREST | 030995 | /0444 | |
Aug 05 2013 | CITIBANK N A , AS ADMINISTRATIVE AGENT | ISTA PHARMACEUTICALS | RELEASE OF SECURITY INTEREST | 030995 | /0444 | |
Aug 30 2013 | Bausch & Lomb Incorporated | GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT | SECURITY AGREEMENT | 031156 | /0508 | |
Jan 08 2015 | GOLDMAN SACHS LENDING PARTNERS, LLC | BARCLAYS BANK PLC, AS SUCCESSOR AGENT | NOTICE OF SUCCESSION OF AGENCY | 034749 | /0689 | |
Jul 17 2017 | Bausch & Lomb Incorporated | The Bank of New York Mellon | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 043251 | /0932 | |
Feb 13 2018 | LABORATOIRE CHAUVIN S A S | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ONPHARMA INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS IRELAND LIMITED | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS LUXEMBOURG S A R L | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMA POLAND SP Z O O | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | WIRRA IP PTY LIMITED | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS NORTH AMERICA LLC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Valeant Pharmaceuticals International | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT CANADA LP | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Technolas Perfect Vision GmbH | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Valeant Pharmaceuticals International | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT CANADA LP | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Technolas Perfect Vision GmbH | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | SYNERGETICS USA, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | SOLTA MEDICAL, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | SANTARUS, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Salix Pharmaceuticals, Ltd | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | PRECISION DERMATOLOGY, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | ORAPHARMA, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Medicis Pharmaceutical Corporation | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | LABORATOIRE CHAUVIN S A S | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | ECR PHARMACEUTICALS CO , INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | DOW PHARMACEUTICAL SCIENCES, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | COMMONWEALTH LABORATORIES, LLC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | BAUSCH & LOMB PHARMA HOLDINGS CORP | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Bausch & Lomb Incorporated | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS NORTH AMERICA LLC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | WIRRA IP PTY LIMITED | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMA POLAND SP Z O O | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | SYNERGETICS USA, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | SOLTA MEDICAL, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | SANTARUS, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Salix Pharmaceuticals, Ltd | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | PRECISION DERMATOLOGY, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ORAPHARMA, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ONPHARMA INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Medicis Pharmaceutical Corporation | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ECR PHARMACEUTICALS CO , INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | DOW PHARMACEUTICAL SCIENCES, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | COMMONWEALTH LABORATORIES, LLC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | BAUSCH & LOMB PHARMA HOLDINGS CORP | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Bausch & Lomb Incorporated | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ATON PHARMA, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS IRELAND LIMITED | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS LUXEMBOURG S A R L | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | ATON PHARMA, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Mar 08 2019 | Bausch & Lomb Incorporated | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | SALIX PHARMACEUTICALS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | PRECISION DERMATOLOGY, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | ORAPHARMA, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | SANTARUS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | Medicis Pharmaceutical Corporation | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | SOLTA MEDICAL, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | BAUSCH HEALTH US, LLC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | BAUSCH HEALTH AMERICAS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Jun 08 2021 | PRECISION DERMATOLOGY, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | BAUSCH HEALTH AMERICAS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | ORAPHARMA, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | SANTARUS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | Medicis Pharmaceutical Corporation | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | SOLTA MEDICAL, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | Bausch & Lomb Incorporated | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | BAUSCH HEALTH US, LLC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | SALIX PHARMACEUTICALS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Feb 10 2022 | ORAPHARMA, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | Bausch & Lomb Incorporated | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | BAUSCH HEALTH US, LLC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | SOLTA MEDICAL, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | Medicis Pharmaceutical Corporation | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | PRECISION DERMATOLOGY, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | BAUSCH HEALTH AMERICAS, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | SANTARUS, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | SALIX PHARMACEUTICALS, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
May 10 2022 | Bausch & Lomb Incorporated | CITIBANK, N A AS COLLATERAL AGENT | PATENT SECURITY AGREEMENT | 059913 | /0548 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 18 2022 | The Bank of New York Mellon | The United States of America, as represented by the Secretary, Department of Health and Human Services | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 18 2022 | The Bank of New York Mellon | Technolas Perfect Vision GmbH | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 18 2022 | The Bank of New York Mellon | LABORATOIRE CHAUVIN S A S | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 056811 0814 | 061872 | /0669 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 059121 0001 | 061873 | /0001 | |
Oct 18 2022 | The Bank of New York Mellon | BAUSCH HEALTH COMPANIES INC | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 18 2022 | The Bank of New York Mellon | Technolas Perfect Vision GmbH | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 18 2022 | The Bank of New York Mellon | The United States of America, as represented by the Secretary, Department of Health and Human Services | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 19 2022 | BARCLAYS BANK PLC | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 034749 0689 | 061778 | /0146 | |
Oct 19 2022 | BARCLAYS BANK PLC | University of Rochester | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 034749 0689 | 061778 | /0146 | |
Oct 19 2022 | BARCLAYS BANK PLC | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 031156 0508 | 061778 | /0446 | |
Oct 19 2022 | BARCLAYS BANK PLC | LABORATOIRE CHAUVIN S A S | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | The United States of America, as represented by the Secretary, Department of Health and Human Services | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | PF Consumer Healthcare 1 LLC | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | Technolas Perfect Vision GmbH | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Sep 29 2023 | Bausch & Lomb Incorporated | CITIBANK, N A , AS NOTES COLLATERAL AGENT | PATENT SECURITY AGREEMENT | 065120 | /0086 |
Date | Maintenance Fee Events |
Jan 04 2010 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Jan 08 2014 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Dec 20 2017 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Jul 18 2009 | 4 years fee payment window open |
Jan 18 2010 | 6 months grace period start (w surcharge) |
Jul 18 2010 | patent expiry (for year 4) |
Jul 18 2012 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jul 18 2013 | 8 years fee payment window open |
Jan 18 2014 | 6 months grace period start (w surcharge) |
Jul 18 2014 | patent expiry (for year 8) |
Jul 18 2016 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jul 18 2017 | 12 years fee payment window open |
Jan 18 2018 | 6 months grace period start (w surcharge) |
Jul 18 2018 | patent expiry (for year 12) |
Jul 18 2020 | 2 years to revive unintentionally abandoned end. (for year 12) |